Physician profile
Wasim Samara
NPI 1275995177
$2,982.22
in general payments reported to CMS, 2019-2025
14 companies · $353 in 2025
The $353 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $27.78 · 2021: $228 · 2022: $643 · 2023: $667 · 2024: $728 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,748.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $847.20 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $588.78 | 2022-2025 | Vabysmo |
| Abbvie INC. | $417.06 | 2022-2025 | Ozurdex |
| Eyepoint US, INC. | $332.21 | 2022-2023 | |
| Alcon Vision LLC | $281.35 | 2019-2022 | |
| Omeros Corporation | $125.00 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $95.11 | 2021 | |
| Apellis Pharmaceuticals, INC. | $92.14 | 2022 | |
| Alimera Sciences, INC. | $56.80 | 2021-2024 | Iluvien, Yutiq |
| Bausch & Lomb Americas INC. | $48.03 | 2024-2025 | Xipere, Visudyne |
| Sandoz INC. | $32.02 | 2024 | Cimerli |
| Astellas Pharma US INC | $26.39 | 2025 | Izervay |
| Coherus Oncology, INC. | $24.58 | 2023 | |
| Notal Vision, INC. | $15.55 | 2024 | Foresee Home |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wasim Samara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.